{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:20:48Z","timestamp":1791073248369,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.lanepe.2025.101359","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T15:55:37Z","timestamp":1750262137000},"page":"101359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting smouldering neuroinflammation in multiple sclerosis: insights from tolebrutinib clinical trials"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6329-8946","authenticated-orcid":false,"given":"Maria","family":"Trojano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damiano","family":"Paolicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lanepe.2025.101359_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanepe.2025.101359_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2415985","article-title":"Tolebrutinib versus teriflunomide in relapsing multiple sclerosis","author":"Oh","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanepe.2025.101359_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lanepe.2025.101359_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54430-8","article-title":"BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis","volume":"15","author":"Gruber","year":"2024","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.lanepe.2025.101359_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/WCO.0000000000001269","article-title":"Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations","volume":"37","author":"Kr\u00e4mer","year":"2024","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.lanepe.2025.101359_bib6","unstructured":"Oh J, Fox RJ, Arnold DL, et al. LB1.1. Paramagnetic rim lesions as a prognostic and predictive biomarker in the tolebrutinib phase 3 trials for disability outcomes. Presented at: 2025 ACTRIMS forum; February 27-March 1; West Palm Beach, FL."},{"issue":"1","key":"10.1016\/j.lanepe.2025.101359_bib7","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209444","article-title":"Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis","volume":"103","author":"Ciccarelli","year":"2024","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.lanepe.2025.101359_bib8","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/ana.27034","article-title":"Smouldering-associated worsening in multiple sclerosis: an international consensus statement on definition, biology, clinical implications, and future directions","volume":"96","author":"Scalfari","year":"2024","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.lanepe.2025.101359_bib9","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1007\/s00330-023-10482-w","article-title":"Looking at the rim in multiple sclerosis: new MRI-based biomarkers may open our eyes to the disease\u2019s evolution","volume":"34","author":"Brisset","year":"2024","journal-title":"Eur Radiol"},{"key":"10.1016\/j.lanepe.2025.101359_bib10","article-title":"Fluid biomarkers in multiple sclerosis: from current to future applications","volume":"44","author":"Di Filippo","year":"2024","journal-title":"Lancet Reg Health Eur"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776225001516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776225001516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T03:34:05Z","timestamp":1773372845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776225001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":10,"alternative-id":["S2666776225001516"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2025.101359","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting smouldering neuroinflammation in multiple sclerosis: insights from tolebrutinib clinical trials","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2025.101359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101359"}}